Please login to the form below
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Cost-effectiveness threshold (health economics)
The ceiling incremental cost-effectiveness ratio (ICER) beyond which interventions are no longer considered cost effective, reflecting the maximum value decision makers attach to health benefits. This may be stated in terms of cost per quality adjusted life year (QALY) gained.
See also:
Decision making unit (DMU)
Cost–benefit analysis
Cost-effective (healthcare economics)
Cost-effectiveness league table (healthcare economics)
Cost-minimisation analysis (CMA)
Cost consequences analysis (CCA)
Related terms
Health Status Instrument (Pharmacoeconomics), Managed care, Porter's 'Five Forces', Compliance, Internal communications, Respondent, NHS Executive, Prescribing information, Commission on Human Medicines (CHM), National Institute for Health and Clinical Excellence (NICE), Foundation Trust (FT), Cost-effectiveness analysis (health economics), Pareto principle , Pharmaceutical Pricing Regulation Scheme (PPRS), NHS Direct,
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- BMS presents positive four-year results for Opdivo combination in lung cancer
- AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
- Merck sues US government over Medicare drug price negotiation programme
- GSK’s RSV vaccine approved by EC for older adults
- The 17th World Congress on Controversies in Neurology
- Medscape Education is Focusing on Patient Centricity and Education Outcomes at EHA 2023
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
No results were found
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
